4D Molecular Therapeutics (FDMT) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
4D Molecular Therapeutics (FDMT) has outperformed Wave Life Sciences (WVE) over the past year, gaining 51.3% versus a loss of 50.8%. Over five years, WVE leads with a -31.3% price change compared with -53.9% for FDMT. 4D Molecular Therapeutics is the larger company by market cap ($679.5 million vs $666.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FDMT | WVE |
|---|---|---|
| Share price | $12.30 | $3.38 |
| Market cap | $679.50M | $666.02M |
| 1-day change | -2.30% | -4.51% |
| YTD return | +67.87% | -79.18% |
| 1-year return | +51.32% | -50.76% |
| 5-year return | -53.92% | -31.26% |
| EPS (TTM) | $-2.63 | $-1.08 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.93 | $21.73 |
| 52-week low | $6.96 | $3.38 |
| Distance from 52-week high | -27.35% | -84.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +128.37% | +434.32% |
| Average volume | 921.65K | 3.10M |
| Shares outstanding | 55.24M | 197.05M |
| Employees | 196 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FDMT has outperformed WVE by 102.1 percentage points over the past year.
About 4D Molecular Therapeutics
FDMT stock →4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 196 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
FDMT vs WVE FAQ
Which is bigger, 4D Molecular Therapeutics or Wave Life Sciences?
4D Molecular Therapeutics (FDMT) is larger, with a market capitalization of $679.50M compared with $666.02M for Wave Life Sciences (WVE).
Which stock has performed better over the past year, FDMT or WVE?
FDMT returned +51.32% over the past 12 months, compared with -50.76% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are 4D Molecular Therapeutics and Wave Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for 4D Molecular Therapeutics and Biotechnology: Pharmaceutical Preparations for Wave Life Sciences.